


**Amendments to the Claims:**

**This listing of claims will replace all prior versions and listing of claims in the application.**

**Listing of Claims:**

Claim 1 (currently amended): A quinazoline derivative of the formula I:



**I**

wherein:

**m** is 0, 1 or 2;

each **R<sup>1</sup>**, which may be the same or different, is selected from hydroxy, (1-6C)alkoxy,

(3-7C)cycloalkyl-oxy and (3-7C)cycloalkyl-(1-6C)alkoxy, and

wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a **R<sup>1</sup>** substituent optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno or (1-6C)alkyl substituents, or a substituent selected from

hydroxy and (1-6C)alkoxy;

**R<sup>2</sup>** is hydrogen or (1-4C)alkyl;

**n** is 0, 1, 2, 3 or 4;

each **R<sup>3</sup>**, which may be the same or different, is selected from cyano, halogeno, (1-4C)alkyl, trifluoromethyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl;

**X<sup>1</sup>** is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>7</sup>), CH(OR<sup>7</sup>), CON(R<sup>7</sup>), N(R<sup>7</sup>)CO, SO<sub>2</sub>N(R<sup>7</sup>), N(R<sup>7</sup>)SO<sub>2</sub>, OC(R<sup>7</sup>)<sub>2</sub>, C(R<sup>7</sup>)<sub>2</sub>O, SC(R<sup>7</sup>)<sub>2</sub>, C(R<sup>7</sup>)<sub>2</sub>S, CO, C(R<sup>7</sup>)<sub>2</sub>N(R<sup>7</sup>) and N(R<sup>7</sup>)C(R<sup>7</sup>)<sub>2</sub>, wherein;

each **R<sup>7</sup>**, which may be the same or different, is hydrogen or (1-6C)alkyl;

**Q<sup>1</sup>** is aryl, or heteroaryl, and

wherein  $Q^1$  optionally bears one or more substituents, which may be the same or different, selected from halogeno, ~~eyano~~, ~~nitro~~, hydroxy, amino, ~~carboxy~~, ~~carbamoyl~~, ~~sulfamoyl~~, ~~formyl~~, ~~mercapto~~, (1-6C)(1-4C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, and (1-6C)(1-4C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxy-carbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (3-6C)alkenoyl, (3-6C)alkynoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino, N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, and a group of the formula:  $-X^2-R^8$  wherein  $X^2$  is a direct bond or is selected from O, CO and N( $R^9$ ), wherein:

$R^9$  is hydrogen or (1-6C)alkyl, and

$R^8$  is ~~halogeno~~ (1-6C)alkyl, hydroxy (1-6C)alkyl, ~~carboxy~~ (1-6C)alkyl, (1-6C)alkoxy (1-6C)alkyl, ~~cyano~~ (1-6C)alkyl, ~~amino~~ (1-6C)alkyl, N-(1-6C)alkylamino (1-6C)alkyl, N,N-di-[(1-6C)alkyl]amino (1-6C)alkyl, (2-6C)alkanoylamino (1-6C)alkyl, N-(1-6C)alkyl-(2-6C)alkanoylamino (1-6C)alkyl, (1-6C)alkoxy-carbonylamino (1-6C)alkyl, ~~carbamoyl~~ (1-6C)alkyl, N-(1-6C)alkylcarbamoyl (1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl (1-6C)alkyl, (1-6C)alkylthio (1-6C)alkyl, (1-6C)alkylsulfinyl (1-6C)alkyl, (1-6C)alkylsulfonyl (1-6C)alkyl, ~~sulfamoyl~~ (1-6C)alkyl, N-(1-6C)alkylsulfamoyl (1-6C)alkyl, N,N-di-[(1-6C)alkyl]sulfamoyl (1-6C)alkyl, (2-6C)alkanoyl (1-6C)alkyl, (2-6C)alkanoyloxy (1-6C)alkyl or (1-6C)alkoxy-carbonyl (1-6C)alkyl, and

wherein any  $CH_2$  or  $CH_3$  group within  $-X^1-Q^1$  optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkylamino];

$R^4$ ,  $R^{4a}$ ,  $R^5$  and  $R^{5a}$ , which may be the same or different, are selected from hydrogen and (1-6C)alkyl, or

$R^4$  and  $R^{4a}$  together with the carbon atom to which they are attached form a (3-7C)cycloalkyl ring, or

$R^5$  and  $R^{5a}$  together with the carbon atom to which they are attached form a (3-7C)cycloalkyl ring, and

wherein any  $CH_2$  or  $CH_3$  group within any of  $R^4$ ,  $R^{4a}$ ,  $R^5$  and  $R^{5a}$  optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno substituents or a substituent selected from hydroxy, cyano, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkylamino];

$R^6$  is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl, and

wherein any heterocyclyl group within an  $R^6$  substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula:

$X^3-R^{10}$ ; wherein

$X^3$  is a direct bond or is selected from O, CO,  $SO_2$  and  $N(R^{11})$ , wherein:

$R^{11}$  is hydrogen or (1-4C)alkyl, and:

$R^{10}$  is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, N-(1-4C)alkylamino-(1-4C)alkyl and N,N-di-[(1-4C)alkyl]amino-(1-4C)alkyl, and

wherein any heterocyclyl group within an  $R^6$  substituent optionally bears 1 or 2 oxo or thioxo substituents, and

wherein any  $CH_2$  or  $CH_3$  group within a  $R^6$  substituent, other than a  $CH_2$  group within a heterocyclyl group, optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,

(2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino;

**A** is selected from hydrogen, a group of the formula  $Z-(CR^{12}R^{13})_p$  and  $R^{14}$ ; wherein

**p** is 1, 2, 3, or 4;

each  $R^{12}$  and  $R^{13}$ , which may be the same or different, is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl,

or an  $R^{12}$  and an  $R^{13}$  group attached to the same carbon atom form a (3-7C)cycloalkyl or (3-7C)cycloalkenyl ring, and

wherein any  $CH_2$  or  $CH_3$  group within any of  $R^{12}$  and  $R^{13}$ , optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, (1-6C)alkyl, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkyl]amino;

**Z** is selected from hydrogen,  $OR^{15}$ ,  $NR^{16}R^{17}$ , (1-6C)alkylsulfonyl, (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, wherein;

each of  $R^{15}$ ,  $R^{16}$  and  $R^{17}$ , which may be the same or different, is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and (1-6C)alkoxycarbonyl,

or **Z** is a group of the formula:  $Q^2-X^4$  wherein;

$X^4$  is selected from O,  $N(R^{18})$ ,  $SO_2$  and  $SO_2N(R^{18})$ , wherein;

$R^{18}$  is hydrogen or (1-6C)alkyl, and;

$Q^2$  is (3-7C)cycloalkyl, (3-7C)cycloalkenyl or heterocyclyl;

$R^{14}$  is selected from hydrogen,  $OR^{19}$  and  $NR^{16}R^{17}$ , wherein;

$R^{19}$  is selected from (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl, and wherein  $R^{16}$  and  $R^{17}$  are as defined above,

or  $R^{14}$  is a group of the formula:  $Q^3-X^5$  wherein;

$X^5$  is selected from O and  $N(R^{20})$ , wherein;

$R^{20}$  is hydrogen or (1-6C)alkyl, and;

$Q^3$  is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl,

or R<sup>14</sup> is Q<sup>4</sup> ~~wherein~~;

Q<sup>4</sup> is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, ~~and~~

wherein adjacent carbon atoms in any (2-6C)alkylene chain within a Z or R<sup>14</sup> substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO<sub>2</sub>,

N(R<sup>21</sup>), CO, -C=C- and -C≡C-, ~~wherein~~;

R<sup>21</sup> is hydrogen or (1-6C)alkyl, ~~and~~

wherein any heterocyclyl group within a Z or R<sup>14</sup> substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula:

-X<sup>6</sup>-R<sup>22</sup>; ~~wherein~~

X<sup>6</sup> is a direct bond or is selected from O, CO, SO<sub>2</sub> and N(R<sup>23</sup>), ~~wherein~~;

R<sup>23</sup> is hydrogen or (1-4C)alkyl, ~~and~~;

R<sup>22</sup> is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, N-(1-4C)alkylamino-(1-4C)alkyl and

N,N-di-[(1-4C)alkyl]amino-(1-4C)alkyl, ~~and~~

wherein any heterocyclyl group within a Z or R<sup>14</sup> substituent optionally bears 1 or 2 oxo or thioxo substituents, and

wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a Z or R<sup>14</sup> group, other than a CH<sub>2</sub> group within a heterocyclyl ring, optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino;

or a pharmaceutically acceptable salt thereof.

Claim 2 (currently amended): ~~A~~The quinazoline derivative according to claim 1, wherein:

**m** is 0, 1 or 2;

each **R**<sup>1</sup>, which may be the same or different, is selected from hydroxy, (1-6C)alkoxy,

(3-7C)cycloalkyl-oxy and (3-7C)cycloalkyl-(1-6C)alkoxy, and

wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a **R**<sup>1</sup> substituent optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno or (1-6C)alkyl substituents, or a substituent selected from hydroxy and (1-6C)alkoxy,

**R**<sup>2</sup> is hydrogen or (1-4C)alkyl;

**n** is 0, 1, 2, 3 or 4;

each **R**<sup>3</sup>, which may be the same or different, is selected from halogeno, (1-4C)alkyl, trifluoromethyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl;

**X**<sup>1</sup> is selected from O, S, SO, SO<sub>2</sub>, N(**R**<sup>7</sup>), CH(OR<sup>7</sup>), CON(**R**<sup>7</sup>), N(**R**<sup>7</sup>)CO, SO<sub>2</sub>N(**R**<sup>7</sup>), N(**R**<sup>7</sup>)SO<sub>2</sub>, OC(**R**<sup>7</sup>)<sub>2</sub>, C(**R**<sup>7</sup>)<sub>2</sub>O, SC(**R**<sup>7</sup>)<sub>2</sub>, C(**R**<sup>7</sup>)<sub>2</sub>S, CO, C(**R**<sup>7</sup>)<sub>2</sub>N(**R**<sup>7</sup>) and N(**R**<sup>7</sup>)C(**R**<sup>7</sup>)<sub>2</sub>, wherein:

each **R**<sup>7</sup>, which may be the same or different, is hydrogen or (1-6C)alkyl;

**Q**<sup>1</sup> is aryl, or heteroaryl, and

wherein **Q**<sup>1</sup> optionally bears one or more substituents, which may be the same or different, selected from halogeno, ~~cyano~~, nitro, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, formyl, mercapto, (1-6C)(1-4C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, and (1-6C)(1-4C)alkoxy,

(2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl,

(1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,

~~N~~ (1-6C)alkylcarbamoyl, ~~N,N~~ di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (3-6C)alkenoyl,

(3-6C)alkynoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,

~~N~~ (1-6C)alkyl (2-6C)alkanoylamino, (3-6C)alkenoylamino, ~~N~~ (1-6C)alkyl (3-

6C)alkenoylamino, (3-6C)alkynoylamino, ~~N~~ (1-6C)alkyl (3-6C)alkynoylamino,

~~N~~ (1-6C)alkylsulfamoyl, ~~N,N~~ di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino,

~~N~~ (1-6C)alkyl (1-6C)alkanesulfonylamino, and a group of the formula:  $\text{--X}^2\text{--R}^8$  wherein

**X**<sup>2</sup> is a direct bond or is selected from O, CO and N(**R**<sup>9</sup>), wherein

~~R<sup>9</sup> is hydrogen or (1-6C)alkyl, and~~

~~R<sup>8</sup> is halogeno (1-6C)alkyl, hydroxy (1-6C)alkyl, carboxy (1-6C)alkyl, (1-6C)alkoxy (1-6C)alkyl, cyano (1-6C)alkyl, amino (1-6C)alkyl, N-(1-6C)alkylamino (1-6C)alkyl, N,N-di-[(1-6C)alkyl]amino (1-6C)alkyl, (2-6C)alkanoylamino (1-6C)alkyl, N-(1-6C)alkyl (2-6C)alkanoylamino (1-6C)alkyl, (1-6C)alkoxycarbonylamino (1-6C)alkyl, carbamoyl (1-6C)alkyl, N-(1-6C)alkylcarbamoyl (1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl (1-6C)alkyl, (1-6C)alkylthio (1-6C)alkyl, (1-6C)alkylsulfinyl (1-6C)alkyl, (1-6C)alkylsulfonyl (1-6C)alkyl sulfamoyl (1-6C)alkyl, N-(1-6C)alkylsulfamoyl (1-6C)alkyl, N,N-di-[(1-6C)alkyl]sulfamoyl (1-6C)alkyl, (2-6C)alkanoyl (1-6C)alkyl, (2-6C)alkanoyloxy (1-6C)alkyl or (1-6C)alkoxycarbonyl (1-6C)alkyl, and~~

wherein any CH<sub>2</sub> or CH<sub>3</sub> group within -X<sup>1</sup>-Q<sup>1</sup> optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkylamino];

R<sup>4</sup>, R<sup>4a</sup>, R<sup>5</sup> and R<sup>5a</sup>, which may be the same or different, are selected from hydrogen and (1-6C)alkyl, or

R<sup>4</sup> and R<sup>4a</sup> together with the carbon atom to which they are attached form a (3-7C)cycloalkyl ring, or

R<sup>5</sup> and R<sup>5a</sup> together with the carbon atom to which they are attached form a (3-7C)cycloalkyl ring, ~~and~~

wherein any CH<sub>2</sub> or CH<sub>3</sub> group within any of R<sup>4</sup>, R<sup>4a</sup>, R<sup>5</sup> and R<sup>5a</sup> optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno substituents or a substituent selected from hydroxy, cyano, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkylamino];

R<sup>6</sup> is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl, and

wherein any heterocyclyl group within an R<sup>6</sup> substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl,

(1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula:

$-X^3-R^{10}$ ; wherein

$X^3$  is a direct bond or is selected from O, CO, SO<sub>2</sub> and N(R<sup>11</sup>); wherein:

R<sup>11</sup> is hydrogen or (1-4C)alkyl, and R<sup>10</sup> is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl,

N-(1-4C)alkylamino-(1-4C)alkyl and N,N-di-[(1-4C)alkyl]amino-(1-4C)alkyl, and

wherein any heterocyclyl group within an R<sup>6</sup> substituent optionally bears 1 or 2 oxo or thioxo substituents; and

wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>6</sup> substituent, other than a CH<sub>2</sub> group within a heterocyclyl group, optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino;

A is selected from hydrogen, a group of the formula Z-(CR<sup>12</sup>R<sup>13</sup>)<sub>p</sub>- and R<sup>14</sup>; wherein

p is 1, 2, 3, or 4,

each R<sup>12</sup> and R<sup>13</sup>, which may be the same or different, is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl,

or an R<sup>12</sup> and an R<sup>13</sup> group attached to the same carbon atom form a (3-7C)cycloalkyl or (3-7C)cycloalkenyl ring, and

wherein any CH<sub>2</sub> or CH<sub>3</sub> group within any of R<sup>12</sup> and R<sup>13</sup>, optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, (1-6C)alkyl, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkyl]amino;



**Z** is selected from hydrogen,  $\text{OR}^{15}$ ,  $\text{NR}^{16}\text{R}^{17}$ , (1-6C)alkylsulfonyl, (1-6C)alkanesulfonylamino and  $\text{N}-(1-6\text{C})\text{alkyl}-(1-6\text{C})\text{alkanesulfonylamino}$ , ~~wherein;~~

each of  $\text{R}^{15}$ ,  $\text{R}^{16}$  and  $\text{R}^{17}$ , which may be the same or different, is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl,

or **Z** is a group of the formula:  $\text{Q}^2-\text{X}^4$ ; ~~wherein~~

$\text{X}^4$  is selected from O,  $\text{N}(\text{R}^{18})$ ,  $\text{SO}_2$  and  $\text{SO}_2\text{N}(\text{R}^{18})$ , ~~wherein;~~

$\text{R}^{18}$  is hydrogen or (1-6C)alkyl, ~~and;~~

$\text{Q}^2$  is (3-7C)cycloalkyl, (3-7C)cycloalkenyl or heterocyclyl;

$\text{R}^{14}$  is selected from hydrogen,  $\text{OR}^{19}$  and  $\text{NR}^{16}\text{R}^{17}$ , ~~wherein;~~

$\text{R}^{19}$  is selected from (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl, and wherein  $\text{R}^{16}$  and  $\text{R}^{17}$  are as defined above,

or  $\text{R}^{14}$  is a group of the formula:  $\text{Q}^3-\text{X}^5$ ; ~~wherein~~

$\text{X}^5$  is selected from O and  $\text{N}(\text{R}^{20})$ , wherein  $\text{R}^{20}$  is hydrogen or (1-6C)alkyl, ~~and;~~

$\text{Q}^3$  is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl,

or  $\text{R}^{14}$  is  $\text{Q}^4$  wherein  $\text{Q}^4$  is (3-7C)cycloalkyl, (3-7C)cycloalkenyl or heterocyclyl, ~~and~~ wherein adjacent carbon atoms in any (2-6C)alkylene chain within a **Z** or  $\text{R}^{14}$  substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO,  $\text{SO}_2$ ,  $\text{N}(\text{R}^{21})$ , CO,  $-\text{C}=\text{C}-$  and  $-\text{C}\equiv\text{C}-$ , ~~wherein;~~

$\text{R}^{21}$  is hydrogen or (1-6C)alkyl, ~~and~~

wherein any heterocyclyl group within a **Z** or  $\text{R}^{14}$  substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula:  $-\text{X}^6-\text{R}^{22}$ ; ~~wherein~~

$\text{X}^6$  is a direct bond or is selected from O, CO,  $\text{SO}_2$  and  $\text{N}(\text{R}^{23})$ , ~~wherein;~~

$\text{R}^{23}$  is hydrogen or (1-4C)alkyl, ~~and;~~

$R^{22}$  is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl,  $\underline{N}$ -(1-4C)alkylamino-(1-4C)alkyl and  $\underline{N,N}$ -di-[(1-4C)alkyl]amino-(1-4C)alkyl, and

wherein any heterocyclyl group within a  $Z$  or  $R^{14}$  substituent optionally bears 1 or 2 oxo or thioxo substituents, and

wherein any  $CH_2$  or  $CH_3$  group within a  $Z$  or  $R^{14}$  group, other than a  $CH_2$  group within a heterocyclyl ring, optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,  $\underline{N}$ -(1-6C)alkylcarbamoyl,  $\underline{N,N}$ -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  $\underline{N}$ -(1-6C)alkyl-(2-6C)alkanoylamino,  $\underline{N}$ -(1-6C)alkylsulfamoyl,  $\underline{N,N}$ -di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and  $\underline{N}$ -(1-6C)alkyl-(1-6C)alkanesulfonylamino; or a pharmaceutically acceptable salt thereof.

Claim 3 (currently amended): ~~A~~The quinazoline derivative according to claim 1, wherein  $R^4$ ,  $R^{4a}$ ,  $R^5$  and  $R^{5a}$ , which may be the same or different, are selected from hydrogen and (1-6C)alkyl, and wherein any  $CH_2$  or  $CH_3$  group within any of  $R^4$ ,  $R^{4a}$ ,  $R^5$  and  $R^{5a}$  optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno substituents or a substituent selected from hydroxy, cyano, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkylamino].

Claim 4 (currently amended): ~~A~~The quinazoline derivative according to claim 1, wherein  $m$  is 0.

Claim 5 (currently amended): ~~A~~The quinazoline derivative according to claim 1, wherein  $R^2$  is hydrogen.

Claim 6 (currently amended): ~~A~~The quinazoline derivative according to claim 1, wherein n is 0, 1 or 2 and, when present, at least one R<sup>3</sup> is in a meta-position (3-position) relative to the nitrogen of the anilino group in formula I.

Claim 7 (currently amended): ~~A~~The quinazoline derivative according to claim 1, wherein n is 1 and R<sup>3</sup> is selected from halogeno and (1-4C)alkyl.

Claim 8 (currently amended): ~~A~~The quinazoline derivative according to claim 7, wherein R<sup>3</sup> is chloro.

Claim 9 (currently amended): ~~A~~The quinazoline derivative according to claim 7, wherein R<sup>3</sup> is methyl.

Claim 10 (currently amended): ~~A~~The quinazoline derivative according to claim 1, wherein X<sup>1</sup> is selected from O, S, OC(R<sup>7</sup>)<sub>2</sub>, SC(R<sup>7</sup>)<sub>2</sub>, SO, SO<sub>2</sub>, N(R<sup>7</sup>), CO and N(R<sup>7</sup>)C(R<sup>7</sup>)<sub>2</sub> wherein each R<sup>7</sup>, which may be the same or different, is selected from hydrogen or (1-6C)alkyl.

Claim 11 (currently amended): ~~A~~The quinazoline derivative according to claim 1, wherein X<sup>1</sup> is selected from O, S and OC(R<sup>7</sup>)<sub>2</sub> wherein each R<sup>7</sup> is, independently, hydrogen or (1-4C)alkyl.

Claim 12 (currently amended): ~~A~~The quinazoline derivative according to claim 1, wherein X<sup>1</sup> is OCH<sub>2</sub>.

Claim 13 (currently amended): ~~A~~The quinazoline derivative according to claim 1, wherein

Q<sup>1</sup> is selected from phenyl and a 5- or 6-membered monocyclic heteroaryl ring, which ring contains 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur, and wherein Q<sup>1</sup> optionally bears one or more substituents, which may be the same or different, selected from halogeno, ~~ciano~~, ~~nitro~~, hydroxy, ~~amino~~, ~~carboxy~~, ~~carbamoyl~~, ~~sulfamoyl~~, ~~formyl~~,

mercapto, (1-6C)(1-4C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, and (1-6C)(1-4C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (3-6C)alkenoyl, (3-6C)alkynoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl (2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl (3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl (3-6C)alkynoylamino, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino, N-(1-6C)alkyl (1-6C)alkanesulfonylamino, and a group of the formula:  $-X^2-R^8$  wherein  $X^2$  is a direct bond or is selected from O, CO and  $N(R^9)$ , wherein  $R^9$  is hydrogen or (1-6C)alkyl, and  $R^8$  is halogeno (1-6C)alkyl, hydroxy (1-6C)alkyl, carboxy (1-6C)alkyl, (1-6C)alkoxy (1-6C)alkyl, cyano (1-6C)alkyl, amino (1-6C)alkyl, N-(1-6C)alkylamino (1-6C)alkyl, N,N-di-[(1-6C)alkyl]amino (1-6C)alkyl, (2-6C)alkanoylamino (1-6C)alkyl, N-(1-6C)alkyl (2-6C)alkanoylamino (1-6C)alkyl, (1-6C)alkoxycarbonylamino (1-6C)alkyl, carbamoyl (1-6C)alkyl, N-(1-6C)alkylcarbamoyl (1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl (1-6C)alkyl, (1-6C)alkylthio (1-6C)alkyl, (1-6C)alkylsulfinyl (1-6C)alkyl, (1-6C)alkylsulfonyl (1-6C)alkyl, (1-6C)alkylsulfamoyl (1-6C)alkyl, N-(1-6C)alkylsulfamoyl (1-6C)alkyl, N,N-di-[(1-6C)alkyl]sulfamoyl (1-6C)alkyl, (2-6C)alkanoyl (1-6C)alkyl, (2-6C)alkanoyloxy (1-6C)alkyl or (1-6C)alkoxycarbonyl (1-6C)alkyl, and wherein any  $CH_2$  or  $CH_3$  group within  $-X^1-Q^1$  optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkylamino].

Claim 14 (currently amended): A The quinazoline derivative according to claim 1, wherein  $Q^1$  is selected from phenyl, pyridyl, pyrazinyl, 1,3-thiazolyl, 1H-imidazolyl, 1H-pyrazolyl, 1,3-oxazolyl and isoxazolyl.

Claim 15 (currently amended): ~~A~~The quinazoline derivative according to claim 1, wherein

$R^6$  is selected from hydrogen, (1-3C)alkyl, (2-3C)alkenyl, (2-3C)alkynyl, (3-5C)cycloalkyl, (3-5C)cycloalkyl-(1-3C)alkyl, heterocyclyl and heterocyclyl-(1-3C)alkyl,

wherein any heterocyclyl group within  $R^6$  is a 4, 5, 6 or 7 membered monocyclic saturated or partially saturated heterocyclyl ring containing 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur, which heterocyclyl group is linked to the group to which it is attached by a ring carbon atom, and

wherein any heterocyclyl group within an  $R^6$  substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula:

$-X^3-R^{10}$ ; wherein

$X^3$  is a direct bond or is selected from O and N( $R^{11}$ ), ~~wherein:~~

$R^{11}$  is hydrogen or (1-4C)alkyl, ~~and;~~

$R^{10}$  is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, N-(1-4C)alkylamino-(1-4C)alkyl and

N,N-di-[(1-4C)alkyl]amino-(1-4C)alkyl, ~~and~~

wherein any heterocyclyl group within an  $R^6$  substituent optionally bears 1 or 2 oxo substituents; and wherein any  $CH_2$  or  $CH_3$  group within a  $R^6$  substituent, other than a  $CH_2$  group within a heterocyclyl group, optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino.

Claim 16 (currently amended): ~~A~~The quinazoline derivative according to claim 15, wherein  $R^6$  is (1-3C)alkyl, and wherein any  $CH_2$  or  $CH_3$  group within a  $R^6$  substituent, other than a  $CH_2$  group within a heterocyclyl group, optionally bears on each said  $CH_2$  or  $CH_3$  group one or more

halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino.

Claim 17 (currently amended): ~~A~~ The quinazoline derivative according to claim 1, wherein

A is selected from a group of the formula  $Z-(CR^{12}R^{13})_p$  and  $R^{14}$ ; ~~wherein~~

p is 1, 2 or 3;

each  $R^{12}$  and  $R^{13}$ , which may be the same or different, is selected from hydrogen and

(1-6C)alkyl, ~~and~~

wherein any  $CH_2$  or  $CH_3$  group within any of  $R^{12}$  and  $R^{13}$  optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno substituents or a substituent selected from hydroxy and (1-6C)alkoxy;

Z is selected from hydrogen,  $OR^{15}$ ,  $NR^{16}R^{17}$  and (1-6C)alkylsulfonyl; ~~wherein;~~

each of  $R^{15}$ ,  $R^{16}$  and  $R^{17}$ , which may be the same or different, is selected from hydrogen, (1-6C)alkyl and (1-6C)alkoxycarbonyl;

$R^{14}$  is selected from  $OR^{19}$  and  $NR^{16}R^{17}$ ; ~~wherein;~~

$R^{19}$  is selected from (1-6C)alkyl and wherein  $R^{16}$  and  $R^{17}$  are as defined above,

or  $R^{14}$  is  $Q^4$ ; ~~wherein;~~

$Q^4$  is (3-7C)cycloalkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, ~~and~~

wherein any heterocyclyl group within a Z or  $R^{14}$  substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, hydroxy, (1-6C)alkyl and (1-6C)alkoxy, and

wherein any  $CH_2$  or  $CH_3$  group within a Z or  $R^{14}$  group, other than a  $CH_2$  group within a heterocyclyl ring, optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy and (1-6C)alkoxy.

Claim 18 (currently amended): ~~A~~ The quinazoline derivative selected from ~~one or more of the~~ following:

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-methoxy-*N*-methylacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-(dimethylamino)-*N*-methylacetamide;

*N*-{(2*R*)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-methoxy-*N*-methylacetamide);

2-hydroxy-*N*-methyl-*N*-{2-[(4-{3-methyl-4-(pyrazin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}acetamide;

2-hydroxy-*N*-methyl-*N*-{2-[(4-{3-methyl-4-(1,3-thiazol-4-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}acetamide;

2-hydroxy-*N*-methyl-*N*-(2-{[4-(3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]anilino)quinazolin-5-yl]oxy}ethyl)acetamide;

*N*-{(2*R*)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-methoxyacetamide;

*N*-(2-{[4-(3-chloro-4-[(6-methylpyridin-2-yl)methoxy]anilino)quinazolin-5-yl]oxy}ethyl)-2-hydroxy-*N*-methylacetamide;

*N*-((2*R*)-2-{[4-(3-chloro-4-[(6-methylpyridin-2-yl)methoxy]anilino)quinazolin-5-yl]oxy}propyl)-2-hydroxy-*N*-methylacetamide;

*N*-(2-{[4-(3-chloro-4-[(6-methylpyridin-2-yl)methoxy]anilino)quinazolin-5-yl]oxy}ethyl)-*N*-methylacetamide;

*N*-(2-{[4-(3-chloro-4-[(2-fluorobenzyl)oxy]anilino)quinazolin-5-yl]oxy}ethyl)-*N*-methylacetamide;

*N*-(2-{[4-(3-chloro-4-[(3-fluorobenzyl)oxy]anilino)quinazolin-5-yl]oxy}ethyl)-*N*-methylacetamide;

*N*-{2-[(4-{3-chloro-4-(1,3-thiazol-4-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-*N*-methylacetamide;

*N*-{2-[(4-{3-chloro-4-(pyrazin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-*N*-methylacetamide;

*N*-{(2*R*)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-hydroxyacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-*N*-methylacetamide;

2-hydroxy-*N*-methyl-*N*-{2-[(4-{3-methyl-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}acetamide;

*N*-{(1*R*)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]-1-methylethyl}acetamide;

*N*-{(1*R*)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]-1-methylethyl}-2-hydroxyacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-methylacetamide;

*N*-(2-{[4-(3-chloro-4-[(3-fluorobenzyl)oxy]anilino)quinazolin-5-yl]oxy}ethyl)-2-hydroxy-*N*-methylacetamide;

*N*-{2-[(4-{3-chloro-4-(1,3-thiazol-4-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-methylacetamide;

*N*-{2-[(4-{3-chloro-4-(pyrazin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-methylacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}acetamide;

*N*-{(2*R*)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}acetamide;

*N*-{(2*R*)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-hydroxy-*N*-methylacetamide;

*N*-{(2*R*)-2-[(4-{3-chloro-4-(pyrazin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-hydroxy-*N*-methylacetamide;

*N*-((2*R*)-2-{[4-(3-chloro-4-[(3-fluorobenzyl)oxy]anilino)quinazolin-5-yl]oxy}propyl)-2-hydroxy-*N*-methylacetamide;

*N*-{(2*R*)-2-[(4-{3-chloro-4-(1,3-thiazol-4-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-hydroxy-*N*-methylacetamide;



*N*-{(2*R*)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-*N*-methylethanacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}-*N*-ethylethanacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}-*N*-ethyl-2-hydroxyethanacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}-*N*-propylethanacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-propylethanacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}-*N*-isopropylethanacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-isopropylethanacetamide;

*N*-allyl-*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}ethanacetamide;

*N*-allyl-*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}-2-hydroxyethanacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}-*N*-cyclopropylethanacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}-*N*-cyclopropyl-2-hydroxyethanacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}-*N*-(cyclopropylmethyl)ethanacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}-*N*-(cyclopropylmethyl)-2-hydroxyethanacetamide;

*N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)phenyl}amino)quinazolin-5-yl)oxy]ethyl}-*N*-cyclobutylethanacetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*-cyclobutyl-2-hydroxyacetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*-(1-methylpiperidin-4-yl)acetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*-(tetrahydro-2*H*-pyran-4-yl)acetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-(tetrahydro-2*H*-pyran-4-yl)acetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*-(2-hydroxyethyl)acetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-(2-hydroxyethyl)acetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*-(2-methoxyethyl)acetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-(2-methoxyethyl)acetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*-prop-2-yn-1-ylacetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-prop-2-yn-1-ylacetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-methylpropanamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*-methyl-tetrahydrofuran-2-carboxamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*,1-dimethylprolinamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*,2-dimethylpropanamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-1-hydroxy-*N*-methylecyclopropanecarboxamide;

*N*<sup>1</sup>-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*<sup>1</sup>,*N*<sup>2</sup>-dimethylglycinamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-3-hydroxy-*N*,2,2-trimethylpropanamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-3-hydroxy-*N*-methylpropanamide;

*N*-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}acetamide;

*N*-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-hydroxyacetamide;

*N*<sup>1</sup>-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-*N*<sup>2</sup>,*N*<sup>2</sup>-dimethylglycinamide;

*N*-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-methoxyacetamide;

*N*-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-(methylsulfonyl)acetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-hydroxyacetamide;

*N*<sup>1</sup>-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*<sup>2</sup>,*N*<sup>2</sup>-dimethylglycinamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-methoxyacetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-(methylsulfonyl)acetamide;

*N*-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-*N*-methylacetamide;

*N*-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-hydroxy-*N*-methylacetamide;

*N*<sup>1</sup>-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-*N*<sup>1</sup>,*N*<sup>2</sup>,*N*<sup>2</sup>-trimethylglycinamide;

*N*-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-methoxy-*N*-methylacetamide;

*N*-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-*N*-methyl-2-(methylsulfonyl)acetamide;

*N*-{(2*R*)-2-[(4-{[3-chloro-4-(pyrazin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-*N*-methylacetamide;

*N*-{(2*R*)-2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-*N*-methylacetamide;

*N*-((2*R*)-2-{[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)-*N*-methylacetamide;

*N*-((2*R*)-2-{[4-({3-chloro-4-[(2-fluorobenzyl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)-*N*-methylacetamide;

*N*-{(1*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-hydroxy-*N*-methylacetamide;

*N*-{(1*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-*N*-methylacetamide;

*N*-{(1*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-hydroxy-*N*-methylacetamide;

*N*-{(1*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-*N*-methylacetamide;

*N*-{(1*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-methoxy-*N*-methylacetamide;

*N*-{(1*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-hydroxyacetamide;

- N*-{(1*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}acetamide;
- N*<sup>1</sup>-{(1*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-*N*<sup>2</sup>,*N*<sup>2</sup>-dimethylglycinamide;
- N*<sup>1</sup>-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-*N*<sup>2</sup>,*N*<sup>2</sup>-dimethylglycinamide;
- (2*S*)-*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2,4-dihydroxybutanamide;
- (2*R*)-*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2,4-dihydroxybutanamide;
- (2*R*)-*N*-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2,4-dihydroxybutanamide;
- (2*S*)-*N*-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2,4-dihydroxybutanamide;
- (2*R*)-*N*-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2,4-dihydroxybutanamide;
- (2*S*)-*N*-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2,4-dihydroxybutanamide;
- (2*S*)-*N*-{(1*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2,4-dihydroxybutanamide;
- (2*R*)-*N*-{(1*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2,4-dihydroxybutanamide;
- (2*R*)-*N*-{2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2,4-dihydroxybutanamide;
- (2*S*)-*N*-{2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2,4-dihydroxybutanamide;
- (2*R*)-*N*-{(1*R*)-2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2,4-dihydroxybutanamide;

(2*S*)-*N*-{(1*R*)-2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]-1-methylethyl}-2,4-dihydroxybutanamide;

*N*-methyl-*N*-{2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]ethyl}acetamide;

*N*-methyl-*N*-{2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]ethyl}acetamide;

*N*-methyl-*N*-(2-{[4-({3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl} amino) quinazolin-5-yl]oxy}ethyl)acetamide;

2-hydroxy-*N*-methyl-*N*-{2-[(4-{[3-methyl-4-(1,3-thiazol-2-ylmethoxy)phenyl] amino} quinazolin-5-yl)oxy]ethyl}acetamide;

2-hydroxy-*N*-{2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]ethyl}acetamide;

2-hydroxy-*N*-{2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]ethyl}acetamide;

*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]-1,1-dimethylethyl}-2-hydroxyacetamide;

2-hydroxy-*N*-{(2*R*)-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]propyl}acetamide;

2-hydroxy-*N*-{(2*R*)-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]propyl}acetamide;

*N*-((2*R*)-2-{[4-({4-[(3-fluorobenzyl)oxy]-3-methylphenyl} amino)quinazolin-5-yl]oxy}propyl)-2-hydroxyacetamide;

2-hydroxy-*N*-{(2*R*)-2-[(4-{[3-methyl-4-(1,3-thiazol-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]propyl}acetamide;

*N*-{(2*R*)-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]propyl}acetamide;

*N*-{(2*R*)-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]propyl}acetamide;

*N*-((2*R*)-2-[[4-({4-[(3-fluorobenzyl)oxy]-3-methylphenyl}amino)quinazolin-5-yl]oxy]propyl)acetamide;

*N*-{(2*R*)-2-[(4-{[3-methyl-4-(1,3-thiazol-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}acetamide;

2-hydroxy-*N*-methyl-*N*-{(2*R*)-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}acetamide;

2-hydroxy-*N*-methyl-*N*-{(2*R*)-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}acetamide;

2-hydroxy-*N*-methyl-*N*-((2*R*)-2-[[4-({3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}amino)quinazolin-5-yl]oxy]propyl)acetamide;

*N*-methyl-*N*-{(1*R*)-1-methyl-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}acetamide;

*N*-methyl-*N*-{(1*R*)-1-methyl-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}acetamide;

*N*-{(1*R*)-2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-hydroxy-*N*-methylacetamide;

2-hydroxy-*N*-methyl-*N*-{(1*R*)-1-methyl-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}acetamide;

2-hydroxy-*N*-methyl-*N*-{(1*R*)-1-methyl-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}acetamide;

*N*-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-1-hydroxy-*N*-methylcyclopropanecarboxamide;

(2*S*)-*N*-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-hydroxy-*N*-methylpropanamide;

*N*-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-hydroxy-*N*,2-dimethylpropanamide;

(2*R*)-*N*-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-hydroxy-*N*-methylpropanamide;

(2*R*)-*N*-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-yl)methoxy]phenyl}amino)quinazolin-5-yl]oxy}propyl}-2-methoxy-*N*-methylpropanamide;

2-hydroxy-*N*-methyl-*N*-((2*R*)-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)acetamide;

*N*-methyl-*N*-((2*R*)-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)acetamide;

*N*<sup>1</sup>,*N*<sup>2</sup>,*N*<sup>2</sup>-trimethyl-*N*<sup>1</sup>-((2*R*)-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)glycinamide;

*N*-methyl-*N*-((2*R*)-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)-2-pyrrolidin-1-ylacetamide;

*N*-methyl-*N*-((2*R*)-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)-2-morpholin-4-ylacetamide;

*N*-methyl-*N*-((2*R*)-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)-2-(4-methylpiperazin-1-yl)acetamide;

2-hydroxy-*N*-methyl-*N*-((2*S*)-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)acetamide;

*N*-methyl-*N*-((2*S*)-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)acetamide;

*N*-methyl-*N*-((2*S*)-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)-2-pyrrolidin-1-ylacetamide;

(2*S*)-2,4-dihydroxy-*N*-((2*R*)-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)butanamide;

(2*S*)-4-bromo-2-hydroxy-*N*-((2*R*)-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)butanamide;

*N*-(2-chloroethyl)-*N*'-((2*R*)-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)urea;




2-hydroxy-*N*-methyl-*N*-((1*R*)-1-methyl-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy} ethyl)acetamide;  
*N*-methyl-*N*-((1*R*)-1-methyl-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy} ethyl)acetamide;  
2-hydroxy-*N*-methyl-*N*-((1*S*)-1-methyl-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy} ethyl)acetamide;  
*N*-methyl-*N*-((1*S*)-1-methyl-2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy} ethyl)acetamide;  
methyl-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]ethyl} methylcarbamate;  
*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]ethyl}-*N,N'*-dimethylurea;  
*N'*-(2-chloroethyl)-*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]ethyl}-*N*-methylurea;  
*N*-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]propyl}-*N'*-methylurea;  
[*((R)*)-2-{4-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl]oxy}propylcarbamoyl)methyl]methylcarbamic acid tert-butyl ester;  
*N*<sup>1</sup>-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]propyl}-*N*<sup>2</sup>-methylglycinamide;  
2-hydroxy-*N*-methyl-*N*-(2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy} ethyl)acetamide;  
*N*-methyl-*N*-(2-{[4-( {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl} amino)quinazolin-5-yl]oxy} ethyl)acetamide; and  
*N*-{2-[(4-{[3-chloro-4-(1-methyl-1-pyridin-2-ylethoxy)phenyl]amino} quinazolin-5-yl)oxy]ethyl}-*N*-methylacetamide;  
or a pharmaceutically acceptable salt thereof.

Claim 19 (previously presented): A pharmaceutical composition which comprises a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 or claim 18 in association with a pharmaceutically-acceptable diluent or carrier.

Claims 20-23 (cancelled).

Claim 24 (currently amended): A process for the ~~preparation of~~ preparing a quinazoline derivative of ~~the~~ formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 which comprises:

a) ~~the~~ coupling, optionally in the presence of a suitable base, ~~of~~ a quinazoline of ~~the~~ formula II:




wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^{4a}$ ,  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $X^1$ ,  $Q^1$ ,  $m$ , and  $n$  have any of the meanings defined in claim 1 except that any functional group is optionally protected, with a carboxylic acid of ~~the~~ formula III, or a reactive derivative thereof:



**III**


wherein A has any of the meanings defined in claim 1 except that any functional group is optionally protected ~~if necessary~~; or

- (b) for the preparation of ~~these the~~ compounds of the formula I wherein  $X^1$  is  $OC(R^7)_2$ ,  $SC(R^7)_2$  or  $N(R^7)C(R^7)_2$ , ~~the reaction reacting, conveniently optionally~~ in the presence of a suitable base, of a quinazoline of the formula IV:



## IV

wherein  $X^{1a}$  is O, S or  $N(R^7)_2$ ; and  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^{4a}$ ,  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^7$ , A, m, and n have any of the meanings defined in claim 1 except that any functional group is optionally protected, with a compound of the formula V or a salt thereof:



## V

wherein  $L^1$  is a suitable displaceable group and  $Q^1$  and  $R^7$  have any of the meanings defined in claim 1 except that any functional group is optionally protected ~~if necessary; or~~


- (c) for the preparation of ~~these the~~ compounds of the formula I wherein A is  $R^{14}$  and  $R^{14}$  is  $NHR^{17}$  or  $Q^3-X^5$ - (wherein  $R^{17}$  and  $Q^3$  are as defined in claim 1 and  $X^5$  is NH), the coupling of a quinazoline of the formula II as defined above in (a) with an isocyanate of the formula IIIa:



## IIIa


wherein A is  $R^{14}$  as previously defined in this section except that any functional group is optionally protected; or

- (d) ~~the reaction of reacting~~ a quinazoline of the formula II wherein  $R^6$  is hydrogen:


**II**

wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^{4a}$ ,  $R^5$ ,  $R^{5a}$ ,  $X^1$ ,  $Q^1$ ,  $m$ , and  $n$  have any of the meanings defined in claim 1 except that any functional group is optionally protected, with  $\alpha$ -hydroxy- $\gamma$ -butyrolactone wherein any functional group is optionally protected; or

(e) the coupling of a quinazoline of the formula VI:


**VI**

wherein  $R^1$ ,  $R^4$ ,  $R^{4a}$ ,  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $A$  and  $m$  have any of the meanings defined in claim 1 except that any functional group is optionally protected, with a compound of the formula IIb:

**IIb**

wherein  $R^2$ ,  $R^3$ ,  $X^1$ ,  $Q^1$  and  $n$  have any of the meanings defined in claim 1 except that any functional group is optionally protected; or


- (f) for the preparation of ~~these the~~ compounds of the formula I wherein  $X^1$  is O and  $Q^1$  is 2-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 2-pyrazinyl or 3-pyridazinyl, ~~the reaction, reacting, conveniently optionally~~ in the presence of a suitable base and a suitable catalyst, of a quinazoline of the formula **VII**:



**VII**


wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^{4a}$ ,  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $A$ ,  $m$  and  $n$  have any of the meanings defined in claim 1 except that any functional group is optionally protected, with 2-bromopyridine, 4-bromopyridine, 2-chloropyrimidine, 4-chloropyrimidine, 2-chloropyrazine or 3-chloropyridazine; or

- (g) for the preparation of ~~these the~~ compounds of the formula I wherein  $A$  is  $Z-(CR^{12}R^{13})_p$ , wherein  $Z$  is  $NR^{16}R^{17}$ , the reaction, ~~conveniently optionally~~ in the presence of a suitable base, of a quinazoline of the formula **VIII**:



**VIII**

wherein  $L^1$  is a suitable displaceable group and  $R^1, R^2, R^3, R^4, R^{4a}, R^5, R^{5a}, R^6, R^{12}, R^{13}, X^1, Q^1, m, n$  and  $p$  have any of the meanings defined in claim 1 except that any functional group is optionally protected, with a compound of the formula **IXa**, or a reactive derivative thereof:



**IXa**

wherein  $R^{16}$  and  $R^{17}$  have any of the meanings defined in claim 1 except that any functional group is optionally protected;

and thereafter, optionally:

- (i) converting a quinazoline derivative of the formula I into another quinazoline derivative of the formula I;
- (ii) removing any protecting group that is present;
- (iii) forming a pharmaceutically acceptable salt.

Claim 25 (currently amended): A method for treating a breast tumour sensitive to inhibition of an ~~erbB2 receptor tyrosine kinase~~ in a warm-blooded animal in need of such treatment, which comprises administering to ~~said the~~ animal an effective amount of a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, according to claim 1.

Claims 26-30 (cancelled).